Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), Resistell AG developed the world’s fastest Antibiotic Susceptibility Testing (AST) platform, delivering ultra-rapid phenotypic results in just 2 hours. This significantly reduces diagnos-tic time, setting a potential new Gold Standard in AST by lowering morbidity, hospital stays, and treatment costs.

Resistell’s core innovation lies in its proprietary nanomotion technology, which detects metabolic changes in living cells. Combined with advanced machine learning algorithms, it offers exceptional accuracy and speed, outperforming traditional methods. The platform is ISO 13485 certified, signaling a major shift in diagnostics.

Resistell’s AST platform is pathogen-agnostic and has been tested for conditions like Urinary Tract Infections and Tuberculosis, as well as Cancer Drug Susceptibility Testing. Proof of con-cept for Antifungal Testing has been demonstrated, and its applications extend to Personalized Cancer Therapy, Drug Discovery, and Cell Viability Assays. With over a dozen industry awards, the technology is secured by international patents.

The core technology has demonstrated over 95% accuracy in AST for bacteremia and sepsis, validated through two clinical studies involving around 470 patient samples and was published in Nature Communications. Building on these successes, Resistell is now finalizing the development of Phenotech MultiStar, a high-throughput diagnostic device designed for the global market.

For further information, please visit the company’s website or contact us directly.

Splint Invest (MARK Investment Holding AG) is revolutionizing access to alternative investments by enabling private investors to invest in exclusive assets and collectibles such as art, whisky, watches and more - from as little as 50 euros. The platform takes care of the legal structure, tokenization and custody, making it much easier to enter these markets.

A particular highlight: Splint Invest concluded a successful deal on the TV show “Höhle der Löwen Schweiz”, which further accelerated its growth. With over 15,000 active users and more than 21 million euros in invested capital, the platform is showing impressive growth rates. Splint Invest makes alternative investments accessible to everyone - simply, securely and transparently.

Thanks to the secondary market integrated on the platform, investors can flexibly sell their investments before maturity, providing them with additional liquidity. The platform is growing rapidly and offers unique potential for investors who want to be at the forefront of innovation in the field of alternative investments.

Currently, MARK Investment Holding AG from Zug, the parent company of Splint Invest, is offering private investors the opportunity to participate in the current financing round. This offers investors the chance to benefit from the company's rapid growth and long-term prospects.

For further information, please visit the company's website or contact us directly.

The cleantech company Whitecell Power AG, with three locations in Switzerland and Germany, develops pioneering emission-neutral drive systems for medium and long-distance transportation in the logistics sector.

The company produces powerful electric drives for freight transport, which are electrically charged during the journey by converting green biomethanol into hydrogen and finally by a fuel cell.

This combination of different technological approaches unites the advantages of powerful electric motors with the zero emissions of biomethanol and hydrogen. The problem of short ranges of electric drives and long charging processes is almost eliminated by the stationary charging process of the batteries and the efficiency of hydrogen is almost doubled compared to conventional combustion.

Whitecell Power AG is one of the pioneers in the field of emission-free electromobility with its solutions, particularly in view of the EU's climate packages, which stipulate a CO2 reduction of up to 50% in freight transport by 2030, and is therefore strongly positioned. The company is already operational and has announced sales in the region of CHF 13 million for this year.

The Series A financing round of CHF 18 million that has now been initiated will be used for a further acquisition, research & development and the small series production of medium-sized vans and heavy trucks.

For further information, please visit the company's website or contact us directly.

Securecell AG is a high-tech life science company with platform technologies for bioprocesses in biopharmaceuticals as well as for relevant breakthrough applications in medical technology.

In the biotech sector, Securecell sells proprietary software and hardware solutions for fully automated cell cultivation and process monitoring for a large number of multinationals in the pharmaceutical and food industries. The company has more than 25 years of experience in this field.

In the medtech field, Securecell is working on radically unique and patent-protected innovations that fundamentally change blood glucose measurement and control in intensive care units. They remove the current therapeutic limitations in diabetes treatment through direct communication and interaction with the blood, enabling diabetes patients to live better. Securecell thus has the potential to become the diabetes industry’s "game changer".

For further information, please visit the Securecell AG company homepage, or contact us directly.

TOPADUR’s vision is to improve the quality of life of patients by providing highly effective and safe medicines, with a focus on wound healing and preservation of vision.
Ageing processes are characterised by a reduction in blood circulation and a dysregulation of cell to cell communication. An imbalance of cGMP levels leads to diseases such as chronic wounds, skin fibrosis, glaucoma, colon cancer, hair loss and skin ageing.

TOPADUR has discovered new compounds and is developing drugs that target the cGMP enzyme regulatory system. The compounds regulate the activity of sGC and PDE5 enzymes to increase cGMP levels. This ultimately enables blood flow and corrects inadequate cell to cell communication.

In addition to annual placements in the top 100 Swiss start-ups in recent years – and winning the Venture Leaders in Life Science Award in 2016 – the company has been awarded various CTI grants and Innosuisse grants. TOPADUR Pharma AG was also able to recruit Dr Daniel L. Vasella as a new member of its Board of Directors.

For further information, please visit the company’s homepage, or contact us directly.